CP
JAZZ icon

Castleview Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Castleview Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$159 – 691
2022
Q4 		$159 Buy
+1
New +$147 ﹤0.01% 620

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Castleview Partners's JAZZ Position: Q1 2023 in Review

Castleview Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 1 share — an estimated $159 sold.

Castleview Partners first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $159 in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • Castleview Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Castleview Partners sold 1 Jazz Pharmaceuticals share in Q1 2023, an estimated $159.
  • Castleview Partners first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Castleview Partners's Jazz Pharmaceuticals position peaked at $159 in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.